Lead Product(s): Pemafibrate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2020
Trial will evaluate if lowering triglycerides and increasing functional HDL with Kowa's potent, selective peroxisome proliferator activator receptor-alpha modulator, K-877.